查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1522124

獸醫骨科生物製劑市場 - 全球產業規模、佔有率、趨勢、機會和預測（按產品、動物、應用、交付模式、最終用戶、地區和競爭細分，2019-2029 年）

Veterinary Orthobiologics Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Product, By Animal, By Application, By Delivery Mode, By End User, By Region & Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年，全球獸醫骨科生物製品市場價值為6.8985 億美元，預計在預測期內將出現令人印象深刻的成長，到2029 年複合年成長率為8.15%。 ，這主要是由於盛行率上升這些條件。這種成長是由幾個關鍵因素推動的，包括人口變化、技術進步和不斷發展的醫療保健實踐。值得注意的是，老年人口的增加與肌肉骨骼疾病的發生率升高直接相關，從而推動了對相關療法和治療的需求。

市場概況
預測期 2025-2029
2023 年市場規模 68985萬美元
2029 年市場規模 110637萬美元
2024-2029 年複合年成長率 8.15%
成長最快的細分市場 富含血小板血漿 (PRP)
最大的市場 北美洲

促進市場成長的主要趨勢包括採用骨科生物製劑、擴大獸醫服務、增加研發投資。然而，市場也面臨治療成本高、監管障礙和標準化變化等挑戰。對這些動態的透徹了解可以為了解受肌肉骨骼疾病發病率上升影響的全球市場提供寶貴的見解。

主要市場促進因素

肌肉骨骼疾病的發生率上升

增加寵物擁有量和寵物的人性化

再生醫學的技術進步

主要市場挑戰

治療費用高

監管和核准挑戰

意識和教育有限

主要市場趨勢

再生醫學和技術的進步

寵物主人的意識和接受度不斷提高

肌肉骨骼疾病的盛行率不斷增加

細分市場洞察

產品洞察

動物洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球獸用骨科生物製劑市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品（幹細胞、富血小板血漿（PRP）、其他）
    • 依動物分類（犬、馬、其他）
    • 依應用（骨關節炎、退化性關節病變、其他）
    • 依輸送方式（肌肉內/病灶內、關節內、其他）
    • 按最終使用者（獸醫院、獸醫院、其他）
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖

第 6 章：北美獸用骨科生物製劑市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按動物分類
    • 按申請
    • 按交付方式
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲獸用骨科生物製劑市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按動物分類
    • 按申請
    • 按交付方式
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區獸用骨科生物製劑市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按動物分類
    • 按申請
    • 按交付方式
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲獸用骨科生物製劑市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按動物分類
    • 按申請
    • 按交付方式
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲獸醫骨科生物製劑市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按動物分類
    • 按申請
    • 按交付方式
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章：全球獸用骨科生物製劑市場：SWOT 分析

第14章：競爭格局

  • Zoetis Services LLC
  • Boehringer Ingelheim International GmbH
  • Ardent Animal Health
  • Enso Discoveries, LLC
  • VetStem, Inc
  • MEDREGO LLC
  • Arthrex, Inc.
  • Hilltop Biosciences
  • Enovis Corporation
  • Dechra Pharmaceuticals Limited

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 24401

Global Veterinary Orthobiologics Market was valued at USD 689.85 Million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.15% through 2029. The global market for managing musculoskeletal disorders is experiencing rapid expansion, primarily due to the rising prevalence of these conditions. This growth is fueled by several key factors, including demographic shifts, advancements in technology, and evolving healthcare practices. Notably, the increase in the elderly population is directly linked to a higher incidence of musculoskeletal disorders, thereby driving demand for related therapies and treatments.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 689.85 Million
Market Size 2029USD 1106.37 Million
CAGR 2024-20298.15%
Fastest Growing SegmentPlatelet-Rich Plasma (PRP)
Largest MarketNorth America

Key trends contributing to market growth include the adoption of orthobiologics, the expansion of veterinary services, and increased investment in research and development. However, the market also faces challenges such as high treatment costs, regulatory hurdles, and variability in standardization. A thorough understanding of these dynamics offers valuable insights into the global market influenced by the escalating incidence of musculoskeletal disorders.

Key Market Drivers

Rising Incidence of Musculoskeletal Disorders

Musculoskeletal disorders, such as arthritis, hip dysplasia, cruciate ligament injuries, and tendonitis, are increasingly common among both companion animals and livestock. The growing prevalence of these conditions creates a heightened demand for effective treatment options. Orthobiologic therapies, which include Platelet-Rich Plasma (PRP), stem cell therapy, and bone grafts, offer advanced solutions for managing these disorders, driving their adoption in veterinary practice. As musculoskeletal disorders become more prevalent, there is a growing preference for non-surgical treatment options that provide effective relief and improve quality of life. Orthobiologics offer minimally invasive alternatives to traditional surgery, addressing the need for less invasive and more efficient therapeutic options. This shift towards non-surgical treatments fuels market growth by making orthobiologic therapies more appealing to both veterinarians and pet owners. The increasing incidence of musculoskeletal disorders necessitates the development and availability of a diverse range of treatment options. Orthobiologic therapies provide a variety of solutions tailored to different types of musculoskeletal issues and animal species. This diversity in treatment options helps address the specific needs of animals suffering from various disorders, further driving the growth of the orthobiologics market.

The rising incidence of musculoskeletal disorders has led to a greater emphasis on early diagnosis and preventive care in veterinary medicine. Veterinarians are increasingly adopting orthobiologic therapies as part of proactive treatment plans aimed at managing and mitigating the progression of musculoskeletal conditions before they become severe. This focus on early intervention promotes the use of orthobiologics and contributes to market growth. Advancements in diagnostic technologies enable earlier and more accurate detection of musculoskeletal disorders. Early diagnosis allows for timely intervention with orthobiologic treatments, which can prevent the escalation of conditions and enhance treatment outcomes. The ability to diagnose and address issues at an early stage drives demand for orthobiologic therapies and supports market expansion. As the incidence of musculoskeletal disorders rises, there is increased awareness among veterinarians about the benefits of orthobiologic treatments. Continued education and training in advanced treatment options encourage veterinarians to incorporate orthobiologics into their practice, thereby driving market growth.

The rising prevalence of musculoskeletal disorders leads to higher expenditure on veterinary care. Pet owners and livestock managers are willing to invest in advanced treatments, including orthobiologics, to manage and alleviate the impact of these disorders. This increased spending supports market growth by creating a larger consumer base for orthobiologic products and services. The demand for orthobiologic treatments driven by the rising incidence of musculoskeletal disorders encourages the establishment and expansion of veterinary practices specializing in orthopedics and regenerative medicine. The growth of these specialized practices enhances the availability and accessibility of orthobiologic therapies, contributing to market expansion. The growing incidence of musculoskeletal disorders stimulates investment in research and development focused on improving orthobiologic treatments. Pharmaceutical companies, biotechnology firms, and research institutions are motivated to develop new and enhanced therapies to address the needs of a growing patient population. This R&D investment drives innovation and supports the growth of the orthobiologics market.

Increasing Pet Ownership and Humanization of Pets

The rise in pet ownership globally results in a larger population of pets requiring veterinary care. As the number of pets increases, so does the incidence of various health issues, including musculoskeletal disorders. This growing pet population translates into a higher demand for effective treatments, including orthobiologics, to manage and alleviate these conditions. With more households owning pets, the market for veterinary products and services, including orthobiologics, expands accordingly. The larger pet owner base creates a broader market for advanced therapeutic options, driving growth in the veterinary orthobiologics sector. As pet ownership increases, so does the expenditure on pet healthcare. Pet owners are increasingly willing to invest in advanced medical treatments to ensure the well-being of their animals. This willingness to spend on high-quality care, including orthobiologic treatments, boosts market growth by increasing demand for these advanced therapies.

The trend of treating pets as family members-often referred to as the humanization of pets-leads to a heightened focus on their health and quality of life. Pet owners who view their animals as integral parts of their families are more likely to seek out advanced and comprehensive medical treatments for their pets, including orthobiologics. As pets are increasingly viewed as family members, there is a growing demand for advanced medical treatments that are comparable to human healthcare. Orthobiologic therapies, which offer cutting-edge solutions for managing musculoskeletal disorders, align with this demand. The humanization trend drives pet owners to explore and invest in these sophisticated treatments to provide the best possible care for their pets. The emotional bond between pet owners and their pets drives a strong desire to alleviate any suffering and improve the quality of life of their animals. This emotional connection motivates pet owners to opt for advanced treatments, such as orthobiologics, to address musculoskeletal disorders and enhance their pets' comfort and mobility.

The humanization of pets also fosters an increased emphasis on preventive and proactive care. Pet owners and veterinarians are more inclined to adopt early intervention strategies to manage musculoskeletal disorders before they progress to more severe stages. Orthobiologic therapies, which can be used to manage and mitigate the effects of these conditions early on, align with this proactive approach. The growing focus on preventive care and the humanization of pets leads to the development and expansion of veterinary services that cater to advanced medical needs. Veterinary clinics and hospitals are increasingly offering specialized services, including orthobiologic treatments, to meet the demands of conscientious pet owners seeking comprehensive care for their pets. The humanization trend also drives increased awareness and education about advanced treatment options among pet owners. As pet owners become more informed about the benefits of orthobiologic therapies, they are more likely to seek out these treatments for their pets. This increased awareness contributes to the growing adoption of orthobiologic solutions and market expansion.

Technological Advancements in Regenerative Medicine

Recent advancements in stem cell therapy, including improvements in cell extraction, processing, and application techniques, have enhanced the efficacy and safety of treatments for musculoskeletal disorders. New methods for isolating and expanding stem cells ensure higher potency and better integration into damaged tissues. These improvements lead to more effective treatments, which drive demand for orthobiologics. Platelet-Rich Plasma (PRP) therapy has seen significant technological progress, such as the development of automated systems for preparing PRP with higher concentration and quality. Enhanced PRP formulations lead to improved outcomes in treating conditions like arthritis and ligament injuries. The increased effectiveness of PRP therapy boosts its adoption and market growth. Advancements in tissue engineering, such as the development of biomaterials and scaffolds that promote tissue regeneration, support the creation of more effective orthobiologic treatments. These innovations enable the repair and regeneration of damaged musculoskeletal tissues, driving the adoption of orthobiologics as a preferred treatment option.

Technological advancements have broadened the range of conditions that can be effectively treated with orthobiologics. Innovations such as gene editing and bioengineered tissues allow for the development of therapies that address a wider variety of musculoskeletal disorders, from joint degeneration to complex fractures. This expansion of treatment indications increases the market's potential and drives growth. Technological progress enables the customization and personalization of orthobiologic treatments based on individual patient needs. Personalized therapies, which are tailored to the specific condition and biological profile of the animal, offer enhanced effectiveness and reduced risks. The ability to customize treatments drives demand for advanced orthobiologic solutions and contributes to market growth. Advancements in regenerative medicine facilitate the development of combination therapies that integrate orthobiologics with other treatment modalities. For example, combining stem cell therapy with PRP or surgical interventions can enhance overall treatment outcomes. The availability of combination therapies expands the market and drives the adoption of orthobiologics.

Technological innovations often lead to more efficient production processes and reduced costs of orthobiologic products. Advances in manufacturing and processing technologies help lower the costs associated with stem cell and PRP therapies, making these treatments more accessible to a broader range of veterinary practices and pet owners. Reduced costs contribute to increased adoption and market growth. Technological advancements in diagnostic and monitoring tools enhance the ability to assess and track the progress of musculoskeletal disorders and the effectiveness of orthobiologic treatments. Better diagnostic tools lead to more accurate treatment planning and monitoring, which supports the adoption of orthobiologics and drives market growth. As technology advances, more veterinary practices are equipped with the latest orthobiologic treatment technologies. The increased availability of these advanced treatments in veterinary clinics and hospitals drives market growth by making orthobiologic therapies more widely accessible to pet owners and livestock managers.

Key Market Challenges

High Cost of Treatments

Orthobiologic treatments, such as stem cell therapy and Platelet-Rich Plasma (PRP), are often associated with high costs due to the complex and specialized nature of the procedures and the materials used. The expense of harvesting, processing, and administering these treatments can be prohibitive for many pet owners and livestock managers, limiting market access and adoption. Veterinary insurance coverage for advanced treatments like orthobiologics is often limited or non-existent. Many pet insurance plans do not cover the full range of orthobiologic therapies, which can deter owners from pursuing these treatments due to out-of-pocket expenses. This lack of insurance support impacts the overall market potential and accessibility of orthobiologic solutions.

Small and mid-sized veterinary practices may struggle to afford the initial investment in orthobiologic technologies and equipment. This economic constraint can restrict the availability of these treatments, particularly in less affluent regions, and limit the growth of the market.

Regulatory and Approval Challenges

The regulatory landscape for veterinary orthobiologics can be complex and varied across different regions. Navigating the regulatory requirements for approval and commercialization of these products involves rigorous testing, documentation, and compliance processes. This complexity can delay the introduction of new products and increase the cost of bringing them to market. There is significant variability in regulatory standards and requirements for orthobiologic treatments across countries. Different regions may have divergent guidelines for product safety, efficacy, and quality, creating challenges for companies seeking to market their products internationally. This lack of uniformity can hinder market expansion and increase operational challenges for global companies.

The absence of standardized protocols and guidelines for the use of orthobiologics in veterinary medicine can lead to inconsistencies in treatment outcomes and clinical practices. This lack of standardization can impact the credibility and acceptance of orthobiologic therapies among veterinarians and pet owners.

Limited Awareness and Education

Not all veterinarians are fully aware of the benefits and applications of orthobiologic treatments. Limited knowledge and familiarity with these advanced therapies can lead to underutilization and reluctance to adopt new treatment options. This gap in awareness can impede the growth of the market as veterinarians play a crucial role in recommending and administering orthobiologic therapies.

There is a need for more comprehensive educational resources and training programs to inform veterinary professionals about the latest advancements in orthobiologics. Insufficient education and professional development opportunities can hinder the effective implementation of these treatments and limit market growth. The general public, including pet owners, may lack a clear understanding of the benefits and effectiveness of orthobiologic treatments. Misconceptions or insufficient information about these therapies can result in lower demand and adoption rates. Efforts to educate pet owners and enhance public awareness are essential for driving market growth.

Key Market Trends

Advancements in Regenerative Medicine and Technology

Recent advancements in regenerative medicine, particularly in the development of new orthobiologic products such as stem cell therapies, Platelet-Rich Plasma (PRP), and tissue engineering, are significantly driving market growth. Innovations in these areas enhance the efficacy and safety of treatments, offering improved outcomes for a range of musculoskeletal conditions in animals. The integration of advanced technologies, such as automated PRP systems, 3D bioprinting, and gene editing, is transforming the landscape of veterinary orthobiologics. These technologies enable the creation of more precise, effective, and personalized treatment solutions. The increased availability and adoption of these technologies in veterinary practices are expected to boost market growth.

Ongoing research and development efforts are crucial in advancing orthobiologic therapies. Significant investments in R&D by pharmaceutical companies, research institutions, and biotechnology firms are leading to the development of novel products and treatment protocols. As these innovations come to market, they will drive further growth and diversification in the veterinary orthobiologics sector.

Growing Awareness and Acceptance Among Pet Owners

The trend towards the humanization of pets has led to a greater emphasis on providing high-quality, advanced medical care for animals. Pet owners increasingly view their pets as family members and are willing to invest in innovative treatments to improve their pets' health and quality of life. This shift is driving demand for orthobiologic treatments that offer advanced solutions for injuries and degenerative diseases. Educational initiatives by veterinary associations, pet care organizations, and media have increased awareness about the benefits of orthobiologic therapies. Pet owners are becoming more informed about the advantages of treatments such as PRP and stem cell therapy, which contributes to higher adoption rates and market growth.

The expansion of veterinary services and clinics, including those specializing in orthobiologics, is making these treatments more accessible to pet owners. As more veterinary practices incorporate advanced orthobiologic therapies into their service offerings, the market is expected to grow as a result of increased availability and accessibility.

Increasing Prevalence of Musculoskeletal Disorders

The increasing prevalence of musculoskeletal disorders, such as arthritis, ligament injuries, and hip dysplasia, in both companion animals and livestock is a major driver of the veterinary orthobiologics market. Factors such as aging pet populations, sedentary lifestyles, and breed-specific genetic predispositions contribute to the rising incidence of these conditions. The growing incidence of orthopedic conditions creates a strong demand for effective, non-surgical treatment options. Orthobiologic therapies, which offer benefits such as accelerated healing, reduced inflammation, and improved joint function, are increasingly sought after as alternatives to traditional treatments.

There is a growing trend towards proactive and preventive veterinary care, with a focus on early intervention and management of orthopedic conditions. Veterinarians are increasingly using orthobiologic treatments as part of comprehensive care plans to address and manage musculoskeletal issues before they become severe, driving market demand.

Segmental Insights

Product Insights

Based on the category of Product, the Platelet-Rich Plasma (PRP) segment emerged as the dominant in the global market for Veterinary Orthobiologics in 2023. PRP therapy utilizes a concentration of platelets derived from the animal's blood, rich in growth factors that stimulate healing and tissue regeneration. This makes PRP highly effective in treating a range of musculoskeletal conditions, including tendonitis, osteoarthritis, and ligament injuries, ensuring quicker recovery times and improved outcomes. PRP procedures are minimally invasive, involving simple blood draws and injections. This reduces the risk of complications and promotes faster recovery compared to surgical interventions. The simplicity and safety of PRP treatments make them an attractive option for both pet owners and veterinarians. Continuous advancements in PRP preparation technologies have enhanced the efficacy and consistency of treatments. Innovations such as automated PRP centrifuges and advanced concentration techniques ensure high-quality PRP formulations, which are crucial for successful therapeutic outcomes.

Technological improvements have also made PRP systems more accessible to veterinary clinics of various sizes. Portable PRP kits and systems allow veterinarians to prepare and administer PRP treatments in-house, eliminating the need for external laboratory services and reducing overall treatment costs. Increasing awareness among pet owners and livestock producers about the benefits of PRP therapy drives demand. Educational efforts by veterinary associations, coupled with positive clinical outcomes, have led to broader acceptance and adoption of PRP treatments. The versatility of PRP in treating a wide range of conditions across different animal species, including horses, dogs, and cats, enhances its appeal. PRP is used not only in orthopedics but also in wound healing and dermatological applications, expanding its market potential. These factors are expected to drive the growth of this segment.

Animal Insights

The canine segment is projected to experience rapid growth during the forecast period. Dogs are among the most popular pets globally, with a significant percentage of households owning one or more dogs. This high rate of pet ownership naturally drives demand for veterinary services, including orthobiologic treatments, to address various musculoskeletal conditions. The increasing trend of treating pets as family members has led to a greater willingness among pet owners to invest in advanced medical treatments. This humanization trend is particularly strong in the canine segment, where owners are keen to provide the best possible care for their dogs, including orthobiologics for injuries and degenerative diseases.

The field of veterinary medicine has seen significant advancements in the development of orthobiologic treatments tailored specifically for canines. These treatments, including stem cell therapy, Platelet-Rich Plasma (PRP), and bone graft substitutes, have proven highly effective in promoting healing and enhancing the quality of life for dogs suffering from orthopedic conditions. The rise of specialized veterinary practices focused on orthopedics and regenerative medicine has made advanced treatments more accessible to dog owners. These practices often offer cutting-edge orthobiologic therapies, contributing to the growth and dominance of the canine segment. Dogs are prone to various orthopedic issues such as arthritis, ligament injuries (e.g., cranial cruciate ligament tears), and hip dysplasia. The prevalence of these conditions creates a substantial and consistent demand for effective treatment options, including orthobiologics. These factors collectively contribute to the growth of this segment.

Regional Insights

North America emerged as the dominant in the global Veterinary Orthobiologics market in 2023, holding the largest market share in terms of value. North America boasts one of the highest per capita healthcare expenditures in the world, which translates into substantial investment in veterinary care. Pet owners and livestock producers in the region are more willing to spend on advanced treatments for animals, driving demand for orthobiologic products. The region has a well-established veterinary infrastructure, including numerous veterinary clinics, hospitals, and research institutions. This infrastructure supports the widespread availability and adoption of advanced veterinary treatments, including orthobiologics.

North America is a hub for technological innovation and research in the field of veterinary medicine. Leading universities and research institutions conduct extensive studies on veterinary orthobiologics, fostering continuous advancements and new product developments. This innovation pipeline ensures a steady flow of cutting-edge solutions to the market. The presence of major pharmaceutical and biotechnology companies in the region facilitates strategic partnerships and collaborations. These collaborations often lead to the development and commercialization of new orthobiologic products, further strengthening the market.

Key Market Players

Zoetis Services LLC

Boehringer Ingelheim International GmbH

Ardent Animal Health

Enso Discoveries, LLC

VetStem, Inc

MEDREGO LLC

Arthrex, Inc.

Hilltop Biosciences

Enovis Corporation

Dechra Pharmaceuticals Limited

Report Scope:

In this report, the Global Veterinary Orthobiologics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Orthobiologics Market, By Product:

    Stem Cells Platelet-rich Plasma (PRP) Other

Veterinary Orthobiologics Market, By Animal:

    Canine Equine Others

Veterinary Orthobiologics Market, By Application:

    Osteoarthritis Degenerative Joint Disease Other

Veterinary Orthobiologics Market, By Delivery Mode:

    Intra-muscular/Intra-lesional Intra-articular Others

Veterinary Orthobiologics Market, By End User:

    Veterinary Hospitals Veterinary Clinics Others

Veterinary Orthobiologics Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia-Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Orthobiologics Market.

Available Customizations:

Global Veterinary Orthobiologics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Veterinary Orthobiologics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Stem Cells, Platelet-rich Plasma (PRP), Other)
    • 5.2.2. By Animal (Canine, Equine, Others)
    • 5.2.3. By Application (Osteoarthritis, Degenerative Joint Disease, Other)
    • 5.2.4. By Delivery Mode (Intra-muscular/Intra-lesional, Intra-articular, Others)
    • 5.2.5. By End User (Veterinary Hospitals, Veterinary Clinics, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2023)
  • 5.3. Market Map

6. North America Veterinary Orthobiologics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Animal
    • 6.2.3. By Application
    • 6.2.4. By Delivery Mode
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Veterinary Orthobiologics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Animal
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By Delivery Mode
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Veterinary Orthobiologics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Animal
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By Delivery Mode
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Veterinary Orthobiologics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Animal
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By Delivery Mode
        • 6.3.3.2.5. By End User

7. Europe Veterinary Orthobiologics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Animal
    • 7.2.3. By Application
    • 7.2.4. By Delivery Mode
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Veterinary Orthobiologics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Animal
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By Delivery Mode
        • 7.3.1.2.5. By End User
    • 7.3.2. United Kingdom Veterinary Orthobiologics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Animal
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By Delivery Mode
        • 7.3.2.2.5. By End User
    • 7.3.3. Italy Veterinary Orthobiologics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Animal
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By Delivery Mode
        • 7.3.3.2.5. By End User
    • 7.3.4. France Veterinary Orthobiologics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Animal
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By Delivery Mode
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Veterinary Orthobiologics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Animal
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By Delivery Mode
        • 7.3.5.2.5. By End User

8. Asia-Pacific Veterinary Orthobiologics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Animal
    • 8.2.3. By Application
    • 8.2.4. By Delivery Mode
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Veterinary Orthobiologics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Animal
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By Delivery Mode
        • 8.3.1.2.5. By End User
    • 8.3.2. India Veterinary Orthobiologics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Animal
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By Delivery Mode
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Veterinary Orthobiologics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Animal
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By Delivery Mode
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Veterinary Orthobiologics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Animal
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By Delivery Mode
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Veterinary Orthobiologics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Animal
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By Delivery Mode
        • 8.3.5.2.5. By End User

9. South America Veterinary Orthobiologics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Animal
    • 9.2.3. By Application
    • 9.2.4. By Delivery Mode
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Veterinary Orthobiologics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Animal
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By Delivery Mode
        • 9.3.1.2.5. By End User
    • 9.3.2. Argentina Veterinary Orthobiologics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Animal
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By Delivery Mode
        • 9.3.2.2.5. By End User
    • 9.3.3. Colombia Veterinary Orthobiologics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Animal
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By Delivery Mode
        • 9.3.3.2.5. By End User

10. Middle East and Africa Veterinary Orthobiologics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Animal
    • 10.2.3. By Application
    • 10.2.4. By Delivery Mode
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Veterinary Orthobiologics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Animal
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By Delivery Mode
        • 10.3.1.2.5. By End User
    • 10.3.2. Saudi Arabia Veterinary Orthobiologics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Animal
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By Delivery Mode
        • 10.3.2.2.5. By End User
    • 10.3.3. UAE Veterinary Orthobiologics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Animal
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By Delivery Mode
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Veterinary Orthobiologics Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Zoetis Services LLC
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Financials (If Listed)
    • 14.1.4. Recent Developments
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Boehringer Ingelheim International GmbH
  • 14.3. Ardent Animal Health
  • 14.4. Enso Discoveries, LLC
  • 14.5. VetStem, Inc
  • 14.6. MEDREGO LLC
  • 14.7. Arthrex, Inc.
  • 14.8. Hilltop Biosciences
  • 14.9. Enovis Corporation
  • 14.10.Dechra Pharmaceuticals Limited

15. Strategic Recommendations

16. About Us & Disclaimer